Gender Differences in Psychotropic Medicine Dispensing at a Pharmacy

Total Page:16

File Type:pdf, Size:1020Kb

Gender Differences in Psychotropic Medicine Dispensing at a Pharmacy dose.7 Th is refl ects the need in the fi rst half of the twen- ARTICLE tieth century for safer alternatives to existing psycho- tropic drugs. Gender diff erences in psychotropic During the 1950s, an event referred to as the ‘Psy- medicine dispensing at a pharmacy in chopharmacological Revolution’ forever changed the Melbourne, Australia, 1954 and 1961 face of psychiatric practice.8 In December 1950, French chemist Paul Charpentier synthesised a medicinal sub- Michael Leach and Rebecca Kippen stance called chlorpromazine.9 Over the next two years, this drug was trialled and found to relieve psychotic Abstract agitation, especially manic excitation.10 Chlorproma- An examination of psychotropic dispensing by gender zine was fi rst marketed in December 1952 for the treat- in historic prescription books could help trace the ori- ment of psychiatric disorders and other indications, in- gins of psychopharmacology in Australia. Th is study cluding morning sickness.11 Th e drug was, and still is, examined gender diff erences in psychotropic medicine marketed in Europe and Australia under the brand dispensing at a Melbourne pharmacy during the 1950s name ‘Largactil’. It soon became possible for people suf- and 1960s. Data were sourced from two prescription fering from psychiatric disorders to be successfully books. Numbers of prescriptions dispensed in 1954 and managed with chlorpromazine in the community rath- 1961 were calculated for each gender and adjusted for er than being institutionalised.12 Chlorpromazine be- population size. More prescriptions were dispensed for came the world’s fi rst antipsychotic drug. Th e success females than for males, by factors of 2 and 1.7 to 1 in of chlorpromazine in psychiatry gave birth to the fi eld 1954 and 1961, respectively. Th is diff erential persisted of psychopharmacology and prompted the search for across prescription type (barbiturate psychotropic, non- other targeted psychotropic drugs, with further antip- barbiturate psychotropic, and non-psychotropic). Psy- sychotics and drugs such as tricyclic antidepressants chotropic dispensing shifted from barbiturates (77% in and benzodiazepines becoming available in the 1950s 1954; 38% in 1961) to newer, safer non-barbiturates and 1960s.13 Many of these newly available non-barbi- (23% in 1954; 62% in 1961), irrespective of gender. turate psychotropic medicines had superior safety pro- fi les to the earlier barbiturate drugs. This was a time of Introduction rapid change in the practice of psychiatry and pharma- Prior to the 1950s, there were few eff ective, safe, and cy. humane options for the management of mental health Gender is an example of a demographic factor that disorders. People with mental health disorders were could have infl uenced the uptake of new psychotropic managed to a small extent in the community and to a medicines over the 1950s and 1960s. Compared with large extent in purpose-built asylums, through methods men, women may be less reluctant to seek medical at- such as electroconvulsive therapy and physical restraint tention and more sensitive to market changes.14 In a or through any of a small number of psychotropic prior study of prescription books kept in an English drugs.1,2 Drugs in the barbiturate class were among the community pharmacy over the period 1890-1922, the most commonly used prescription psychotropic medi- drugs of dependence opium, cocaine, and heroin (legal cines in the fi rst half of the twentieth century.3 Th is substances at the time) were more likely to be dispensed drug class takes its name from the fi rst barbiturate bar- to females than to males.15 Th ese results were not, how- bituric acid, which was discovered and named by Ger- ever, adjusted for the sizes of the male and female pop- man chemist Johann Adolf von Baeyer on 4 December ulations in the surrounding geographic area. Many of 1863 – the feast day of St. Barbara.4 the male users of drugs of dependence in this historical Barbiturate use became commonplace in Western study were returned servicemen who served in such society following the marketing of barbitone (brand countries as South Africa and India.16 name Veronal) in 1903.5 While barbiturates have prov- While this study shed some light on gender diff er- en eff ective at inducing sleep, they have also been ences in the utilisation of drugs of dependence between shown to cause a range of adverse eff ects such as un- the 1890s and 1920s, no known studies have examined wanted daytime sedation, comas, and deaths, including gender diff erences in psychotropic use within a com- the deaths of actresses Marilyn Monroe in 1962 and munity pharmacy setting during the 1950s and 1960s Judy Garland in 1969.6 Such a high potential for harm – the period of the Psychopharmacological Revolution. relates to the fact that barbiturates have narrow thera- Women may have been more likely than men to seek peutic indices; there is little diff erence between the dose newly available treatments for mental health disorders, required to eff ectively sedate a patient and the lethal whereas returned servicemen with conditions such as PHARMACEUTICAL HISTORIAN · 2019 · Volume 49/3 65 posttraumatic stress disorder may have also been regu- to 1 June 1956, while the more recent book covers the lar users of psychotropics at this time. Such information period 20 May 1960 to 24 July 1963. Both volumes is of interest in that it lays the foundation for the high contain handwritten information on prescriptions dis- levels of psychotropic use in modern day Australia. pensed by several pharmacists, or pharmaceutical Modern day Australia has been found to have the sec- chemists as they were known at the time. Th e handwrit- ond highest consumption of antidepressants in the ten information includes patients’ titles, patients’ world,17 with women being signifi cantly more likely names, dispensing dates, medicines dispensed, costs, than men to use these medicines.18 An examination of and directions for use. Th e pharmaceutical chemists psychotropic dispensing by gender in historic prescrip- wrote this information in ink on ruled pages, using the tion books could help trace the origins of psychophar- conventional academic language of Latin. Th e dis- macology in Australia. pensed prescriptions appear in each book in chrono- Th is study aimed to examine gender diff erences in logical order. psychotropic medicine dispensing at an Inner South East Melbourne pharmacy during the Psychopharma- Study Design and Data Collection cological Revolution of the 1950s and 1960s. A descriptive study was conducted to examine the vol- ume of medicine dispensing over the calendar years Methods 1954 (book 1) and 1961 (book 2) by gender, prescrip- Data Source tion type, and year. Th ese years were chosen to examine Prescription books can be considered rich yet underu- changes in psychotropic drug utilisation over a period tilised sources of primary historical data on medicine coinciding with the rapid introduction of new psycho- dispensing.19 Prior to the availability of dispensing soft- tropics (antipsychotics, benzodiazepines, and antide- ware, prescription books were used to record all pre- pressants) into the Australian market during the 1950s scribed medicines supplied to customers. Previously, and 1960s. For each prescription recorded in the two 20 21 prescription books dating from the 1850s, 1860s, books over the years 1954 and 1961, the following data 22 23 1900s, and 1960s have been used to broadly describe items were collected: dispensing date, patient title, and the medicines dispensed in individual Australian phar- name of medicine dispensed. Th e title of patients (e.g. macies. In the United Kingdom, meanwhile, prescrip- Mr, Mrs, Sir, and Lady) was used as a marker of gender. tion books dating back to the nineteenth and twentieth Among all medicines dispensed, barbiturate psycho- centuries have been examined to better understand tropics, non-barbiturate psychotropics, and non-psy- temporal changes in the use of diff erent dosage forms chotropic medicines were identifi ed using a published 24, 25, as well as the dispensing of drugs of dependence. list of psychotropics in common use in 195929 as well 26, 27, 28 as the editions of the British Pharmacopoeia30, 31 and Th e data source for the present study is a pair of Martindale: Th e Extra Pharmacopoeia32, 33 that were cur- mid-twentieth-century prescription books that were rent at the time. kept at a community pharmacy in an inner south east suburb of Melbourne, Australia (Figure 1). Each book Inclusion and Exclusion Criteria is bound in leather and measures 41 x 18.7 x 9.7 centi- For each prescription, the inclusion criterion was med- metres. Th e elder of the two books details prescription icine supply during the calendar years 1954 or 1961 medicines dispensed over the period 25 November 1953 while the exclusion criteria were unknown gender (no title), a cancelled prescription, a prescription intended for veterinary use, and handwriting that could not be deciphered by a pharmacoepidemiologist with experi- ence in community pharmacy. Data Analysis A descriptive analysis of eligible prescriptions was con- ducted. Firstly, raw numbers of prescriptions dispensed in 1954 and 1961 were calculated and stratifi ed by pre- scription type (barbiturate psychotropic, non-barbitu- rate psychotropic, or non-psychotropic medicine), year of dispensing, and gender of the patient. Th e raw num- Figure 1. Th e prescription books used to source primary bers were then adjusted for the size of the male and fe- data male populations resident in the local government area 66 PHARMACEUTICAL HISTORIAN · 2019 · Volume 49/3 (LGA) City of Stonnington – where the pharmacy was analysis. In the later period, between 3/1/1961 and located – using Australian census data for the years 29/12/1961, 2,783 prescriptions were recorded in the 195434 and 1961.35 What is now Stonnington com- second Melbourne pharmacy ledger.
Recommended publications
  • Medicines Regulations 1984 (SR 1984/143)
    Reprint as at 1 July 2014 Medicines Regulations 1984 (SR 1984/143) David Beattie, Governor-General Order in Council At the Government House at Wellington this 5th day of June 1984 Present: His Excellency the Governor-General in Council Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that ap- peared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Council, hereby makes the following regulations. Contents Page 1 Title and commencement 5 Note Changes authorised by subpart 2 of Part 2 of the Legislation Act 2012 have been made in this official reprint. Note 4 at the end of this reprint provides a list of the amendments incorporated. These regulations are administered by the Ministry of Health. 1 Reprinted as at Medicines Regulations 1984 1 July 2014 2 Interpretation 5 Part 1 Classification of medicines 3 Classification of medicines 11 Part 2 Standards 4 Standards for medicines, related products, medical 11 devices, cosmetics, and surgical dressings 5 Pharmacist may dilute medicine in particular case 12 6 Colouring substances [Revoked] 12 Part 3 Advertisements 7 Advertisements not to claim official approval 13 8 Advertisements for medicines 13 9 Advertisements for related products 15 10 Advertisements for medical devices 15 11 Advertisements
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al
    USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,005,660 B2 Tygesen Et Al
    USOO9005660B2 (12) United States Patent (10) Patent No.: US 9,005,660 B2 Tygesen et al. (45) Date of Patent: Apr. 14, 2015 (54) IMMEDIATE RELEASE COMPOSITION 4,873,080 A 10, 1989 Bricklet al. RESISTANT TO ABUSEBY INTAKE OF 4,892,742 A 1, 1990 Shah 4,898,733. A 2f1990 DePrince et al. ALCOHOL 5,019,396 A 5/1991 Ayer et al. 5,068,112 A 11/1991 Samejima et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 5,082,655 A 1/1992 Snipes et al. Jan Martin Oevergaard, Frederikssund 5,102,668 A 4, 1992 Eichel et al. 5,213,808 A 5/1993 Bar Shalom et al. (DK); Joakim Oestman, Lomma (SE) 5,266,331 A 11/1993 Oshlack et al. 5,281,420 A 1/1994 Kelmet al. (73) Assignee: Egalet Ltd., London (GB) 5,352.455 A 10, 1994 Robertson 5,411,745 A 5/1995 Oshlack et al. (*) Notice: Subject to any disclaimer, the term of this 5,419,917 A 5/1995 Chen et al. patent is extended or adjusted under 35 5,422,123 A 6/1995 Conte et al. U.S.C. 154(b) by 473 days. 5,460,826 A 10, 1995 Merrill et al. 5,478,577 A 12/1995 Sackler et al. 5,508,042 A 4/1996 OShlack et al. (21) Appl. No.: 12/701.248 5,520,931 A 5/1996 Persson et al. 5,529,787 A 6/1996 Merrill et al. (22) Filed: Feb. 5, 2010 5,549,912 A 8, 1996 OShlack et al.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Tranquillizing and Thymoleptic Drugs in Outpatient and General Practice
    TRANQUILLIZING AND THYMOLEPTIC DRUGS IN OUTPATIENT AND GENERAL PRACTICE BY r R. E. HEMPHILL, M.A., M.D., D.P.M. Lecturer in Mental Health, University of Bristol, Consultant Psychiatrist, Glenside-Barrow and United Bristol Hospitals AND J. E. BARBER, M.B., CH.B., D.(OBST.)R.C.O.G. * Clinical Research Assistant, Barrow Hospital. An account of these drugs was published in this Journal in 1962 (Hemphill, 1962). The present paper is a revision of the earlier survey, and includes a review of the newer drugs and recent developments. For clarity, sections of the original paper have been quoted completely or in part. The numerous preparations are divided for convenience into tranquillizers, anti- depressants and an intermediate group. This classification is clinical, and does not necessarily imply that the drugs in one group have a similar chemical structure or pharmacological action. The effect of these drugs in the human is complex, and is not necessarily the same in the sick as in the mentally well. Anxious persons and those with autonomic instability are particularly sensitive to some, and may develop side effects at a low dosage, in contrast to the usual tolerance of schizophrenics and other psychotics. Since tranquillizers and thymoleptics influence mood and emotion, it is to be expected that they will have an effect on other functions which involve the autonomic nervous system. Control of blood pressure, of intestinal and bladder muscle, and secretion of saliva and alimentary juices, for example, may be interfered with. Hypotension and dry mouth are common side effects, and therapeutic doses of some of the drugs can cause retention of urine and ileus.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,023,394 B2 Andersen Et Al
    USOO9023394B2 (12) United States Patent (10) Patent No.: US 9,023,394 B2 Andersen et al. (45) Date of Patent: *May 5, 2015 (54) FORMULATIONS AND METHODS FOR THE 4,330,338 A 5, 1982 Banker CONTROLLED RELEASE OF ACTIVE DRUG 4.389,393 A 6, 1983 Schor et al. 4.404,183 A 9, 1983 Kawata et al. SUBSTANCES 4,449,983 A 5/1984 Cortese et al. 4,503,067 A 3, 1985 Wiedemann et al. (71) Applicant: Egalet Ltd., London (GB) 4,686,212 A 8, 1987 Ducatman et al. 4,824,675 A 4/1989 Wong et al. (72) Inventors: Christine Andersen, Vedbaek (DK); 4,844,984 A 7, 1989 Eckenhoffetal. 4,873,080 A 10, 1989 Bricklet al. Karsten Lindhardt, Haslev (DK); Jan 4,892,742 A 1, 1990 Shah Martin Oevergaard, Frederikssund 4,898,733. A 2f1990 DePrince et al. (DK); Louise Inoka Lyhne-versen, 5,019,396 A 5/1991 Ayer et al. Gentofte (DK); Martin Rex Olsen, 5,068,112 A 11/1991 Samejima et al. Holbaek (DK); Anne-Mette Haahr, 5,082,655 A 1/1992 Snipes et al. 5,102,668 A 4, 1992 Eichel et al. Birkeroed (DK); Pernille Kristine 5,213,808 A 5/1993 Bar Shalom et al. Hoeyrup Hemmingsen, Bagsvaerd 5,266,331 A 11/1993 Oshlack et al. (DK) 5,281,420 A 1/1994 Kelmet al. 5,352.455 A 10, 1994 Robertson (73) Assignee: Egalet Ltd., London (GB) 5,411,745 A 5/1995 Oshlack et al. 5,419,917 A 5/1995 Chen et al.
    [Show full text]
  • Säädk 415/2019
    SUOMEN SÄÄDÖSKOKOELMA MuuMnrovvvvLääkealanlääkeluettelosta asia turvallisuus- ja kehittämiskeskuksen päätös Julkaistu Helsingissä 29 päivänä maaliskuuta 2019 415/2019 Lääkealan turvallisuus- ja kehittämiskeskuksen päätös lääkeluettelosta Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääkelain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1§ Luettelon tarkoitus Tämä päätös sisältää luettelon Suomessa lääkkeellisessä käytössä olevista aineista ja rohdoksista. Lääkeluettelo laaditaan ottaen huomioon lääkelain 3 §:n ja 5 §:n säännökset. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ul- koisesti käytettynä parantaa, lievittää tai ehkäistä sairautta tai sen oireita ihmisessä tai eläi- messä. Lääkkeeksi katsotaan myös sisäisesti tai ulkoisesti käytettävä aine tai aineiden yh- distelmä, jota voidaan käyttää ihmisen tai eläimen elintoimintojen palauttamiseksi, kor- jaamiseksi tai muuttamiseksi farmakologisen, immunologisen tai metabolisen vaikutuk- sen avulla taikka terveydentilan tai sairauden syyn selvittämiseksi. Lääkeluettelo ei ole tyhjentävä. Tässä luettelossa mainitsemattomat aineet ja rohdokset, jotka täyttävät lääkelain lääkkeen määritelmän, ovat lääkkeitä. Lääkeluettelon vahvistamisen lisäksi Lääkealan turvallisuus- ja kehittämiskeskus päättää lääkelain 6 §:n nojalla tarvittaessa, onko ainetta tai valmistetta pidettävä lääkkeenä. Keskus päättää tapauskohtaisesti onko luettelossa olevaa ainetta sisältävää valmistetta pidettävä lääk- keenä
    [Show full text]
  • Medicines Regulations 1984 (SR 1984/143)
    Reprint as at 30 March 2021 Medicines Regulations 1984 (SR 1984/143) David Beattie, Governor-General Order in Council At the Government House at Wellington this 5th day of June 1984 Present: His Excellency the Governor-General in Council Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that appeared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Coun- cil, hereby makes the following regulations. Contents Page 1 Title and commencement 5 2 Interpretation 5 Part 1 Classification of medicines 3 Classification of medicines 9 Note Changes authorised by subpart 2 of Part 2 of the Legislation Act 2012 have been made in this official reprint. Note 4 at the end of this reprint provides a list of the amendments incorporated. These regulations are administered by the Ministry of Health. 1 Reprinted as at Medicines Regulations 1984 30 March 2021 Part 2 Standards 4 Standards for medicines, related products, medical devices, 10 cosmetics, and surgical dressings 4A Standard for CBD products 10 5 Pharmacist may dilute medicine in particular case 11 6 Colouring substances [Revoked] 11 Part 3 Advertisements 7 Advertisements not to claim official approval 11 8 Advertisements for medicines 11 9 Advertisements for related products 13 10 Advertisements
    [Show full text]
  • Psychotropic Drugs G
    Postgrad Med J: first published as 10.1136/pgmj.60.710.881 on 1 December 1984. Downloaded from Postgraduate Medical Journal (December 1984) 60, 881-885 Psychotropic drugs G. W. HANKS B.Sc., M.B., M.R.C.P. The Royal Marsden Hospital, Fulham Road, London SW3 6JJ Introduction system-depressant effect ofthese drugs: by depressing the general level of arousal the central perception of The interaction between the cognitive component pain may be modified. (the perception ofnociceptive, or painful stimuli) and In this review the evidence for intrinsic analgesic the affective component of pain is reflected in the activity and overlap between the actions of anti-nociceptive the place of psychotropic drugs in the agents (analgesics) and mood-altering drugs (psycho- treatment of chronic pain are discussed in the light of tropics) when treating pain patients. Anxiety, depres- the published literature and recent clinical experi- sion, fear and sleeplessness may all respond to ence. psychotropic drugs, and this may result in a reduc- tion in pain or a greater ability to cope with it. This TABLE 1. The WHO classification of psychotropic drugs may enable a patient's pain to be controlled with a Neuroleptics by copyright. smaller dose of analgesic. In this sense psychotropic Anxiolytic sedatives drugs have an 'analgesic' effect but it is a misleading Antidepressants use of the word, and has been the source of much Psychostimulants misunderstanding. Psychodysleptics In the day-to-day management of pain problems the two groups of drugs do have well-defined indications. Acute pain is invariably associated with Neuroleptics nociception, and responds to analgesics or other Neuroleptics are antipsychotic agents of which the antinociceptive treatments.
    [Show full text]
  • Journal of Pharmacy and Pharmacology 1958 Volume.10 Suppl
    The Journal of PHARMACY and PHARMACOLOGY Successor;sor to The Quarterly Journal o f Pharmacy and PharmacologyPharma 17 BLOOMSBURY SQUARE, LONDON, W.C.l Telephone: HOLborn 8967 Telegrams: Pharmakon, Westcent, London Editor: George Brownlee, D.Sc., Ph.D., F.P.S. Assistant Editor: J. R. Fowler, B.Pharm., F.P.S. CONTENTS BRITISH PHARMACEUTICAL CONFERENCE p a g e R eport o f Proceedings .......................................................................................... IT Chairman’s Address Modern Analytical Chemistry in the Service of Pharmacy and Medicine. By G. E. F o s t e r ..............................................................9 T Symposium E v a l u a t i o n o f N e w D r u g s . By L. G. Goodwin and F. L. Rose .. 24 T Science Papers and Discussions The Basis for “Sufficient of a Suitable Bacteriostatic” in Injec­ tions. By G. Sykes ..........................................................................40 T The Factors Influencing Sterilisation by Low Pressure Steam. Part I. Design and Instrumentation. By T. E. Barson, F. Peacock, E. L. Robins and G. R. Wilkinson .. .. .. .. .. 47 T The Factors Influencing Sterilisation by Low Pressure Steam. Part II. The Influence of Water Content of Cotton Gowns on Equilibrium Times. By T. E. Barson, F. Peacock, E. L. Robins and G. R. W ilk in s o n ..........................................................................56 T The Colorimetric D etermination of Morphine in G alenical Preparations. By C. A. Johnson and Cecilia J. Lloyd .. .. 60 T Some Observations Concerning the Chemical Reactions Occur­ ring Between Formaldehyde and Peptone. By Kenneth Bullock and V. Subba Rao .. .. .. .. .. .. 72 T The Effects of Added Peptone on the Bactericidal Action of Solutions of Formaldehyde.
    [Show full text]
  • Qsar Study of Phenothiazines
    STUDIA UBB CHEMIA, LXI, 1, 2016 (p. 305-316) (RECOMMENDED CITATION) Dedicated to Professor Mircea Diudea on the Occasion of His 65th Anniversary QSAR STUDY OF PHENOTHIAZINES ATENA PÎRVAN MOLDOVANa,*, SARA ERSALIa, RALUCA POPb ABSTRACT. A QSAR study on a set of 30 phenothiazines performed within a hypermolecule frame, to model their logP and LD50 values, is reported. The initial set of molecules was split into a training set and the test set; Cluj topological indices and some quantum mechanical descriptors have been used to derive the models, which were next tested for predictability by LOO, external validation and similarity clustering. Key words: phenothiazine, hypermolecule, LD50, logP, topological indices. INTRODUCTION Phenothiazine is an organic heterocyclic compound, of the class of thiazines, with the brute formula S(C6H4)2NH, of which skeleton occurs in various antipsychotic, antihistaminic, antiemetic, etc. drugs. Phenothiazine was synthesized by Bernthsen in 1883 by melting the diphenylamine with sulfur; its medicamentous derivatives are currently synthesized by the cyclization of substituted diphenylamines or diphenyl sulfides. Synthesis of methylene blue was reported in 1876 and is still used as antiseptic, antihelminthic drug. Phenothiazine antipsychotics, like chlorpromazine and prochlorperazine, are used to treat serious mental and emotional disorders, including schizophrenia and other psychotic disorders. Phenothiazine antipsychotics are classified into three groups, differing with respect to the substituent on nitrogen: the aliphatic compounds, piperidine compounds and piperazine derivatives. As antihistaminic, the promethazine is the most used phenothiazine. a Babeş-Bolyai University, Faculty of Chemistry and Chemical Engineering, 11 Arany Janos str., RO-400028, Cluj-Napoca, Romania b University of Medicine and Pharmacy “Victor Babes” Timisoara, Faculty of Pharmacy, E.
    [Show full text]
  • TCI AMERICA Page 1 of 5 SAFETY DATA SHEET Revision Number: 1.1 Revision Date: 07/06/2018
    TCI AMERICA Page 1 of 5 SAFETY DATA SHEET Revision number: 1.1 Revision date: 07/06/2018 1. IDENTIFICATION Product name: Apronal Product code: A2844 Product use: For laboratory research purposes. Restrictions on use: Not for drug or household use. Company: Emergency telephone number: TCI America Chemical Emergencies: 9211 N. Harborgate Street TCI America (8:00am - 5:00pm) PST Portland, OR 97203 U.S.A. +1-503-286-7624 Telephone: Transportation Emergencies: +1-800-423-8616 / +1-503-283-1681 Chemtrec 24-Hour Fax: +1-800-424-9300 (U.S.A.) +1-888-520-1075 / +1-503-283-1987 +1-703-527-3887 (International) e-mail: Responsible department: [email protected] TCI America www.TCIchemicals.com Environmental Health Safety and Security +1- 503-286-7624 2. HAZARD(S) IDENTIFICATION OSHA Haz Com: CFR 1910.1200: Acute Toxicity - Oral [Category 4] WHMIS 2015: Signal word: Warning! Hazard Statement(s): Harmful if swallowed Pictogram(s) or Symbol(s): Precautionary Statement(s): [Prevention] Do not eat, drink or smoke when using this product. Wash hands and face thoroughly after handling. [Response] If swallowed: Call a poison center or doctor if you feel unwell. Rinse mouth. [Disposal] Dispose of contents and container in accordance with local, regional, national regulations (e.g. US: 40 CFR Part 261, EU:91/156/EEC, JP: Waste Disposal and Cleaning Act, etc.). Hazards not otherwise classified: None. [HNOC] 3. COMPOSITION/INFORMATION ON INGREDIENTS Substance/mixture: Substance Components: Apronal Percent: >98.0%(HPLC)(N) CAS RN: 528-92-7 Molecular Weight: 184.24 Chemical Formula: C9H16N2O2 Synonyms: (2-Isopropyl-4-pentenoyl)urea , Allylisopropylacetylcarbamide , Allylisoprorylacetylurea , Apronalide , N-Carbamoyl-2-isopropyl-4-pentenamide Apronal TCI AMERICA Page 2 of 5 4.
    [Show full text]